Finally, and most importantly, to determine the value of NSUN5 methylation as a candidate independent biomarker, we performed multivariate analysis for NSUN5 methylation status and the described known biomarkers of clinical outcome (IDH1 mutational, 1p/19q co-deletion and MGMT methylation status) for the both studied glioma cohorts. The gene discussed is IDH1; the disease is glioma.